GeneDx to Launch Autism Partnership Program to Expand Access to Exome and Genome Testing, including Dedicated SHANK3 Program
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Business Wire
Jaguar Gene Therapy joins as founding partner to initiate a genetic testing program for SHANK3-related autism spectrum disorder and Phelan-McDermid syndrome GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the Autism Partnership Program to expand access to its industry leading exome and genome testing – the only autism testing program committed to delivering answers to families in weeks. Jaguar Gene Therapy joins the program as the founding partner, initiating a genetic testing program for individuals clinically suspected of having SHANK3-related autism spectrum disorder (ASD) and Phelan-McDermid syndrome. A single pathogenic variant or deletion in the SHANK3 gene is a leading single-gene cause of ASD.By uniting healthcare providers, advocacy groups, biopharmaceutical companies and payers, the Autism Partnership Program aims to eliminate barriers to testing and deliver clinically acti
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- GeneDx to Showcase Advancements in Gene-Disease Discovery, Long-Read Sequencing and More at National Society of Genetic Counselors (NSGC) 2025 Annual MeetingBusiness Wire
- Artificial Intelligence Powered Rare Disease Diagnosis Research Report 2025: Market to Surpass $5.5 Billion by 2029 on Accelerated Adoption of Predictive and Personalized Healthcare - Forecast to 2034 [Yahoo! Finance]Yahoo! Finance
- GeneDx (NASDAQ:WGS) had its price target raised by analysts at Wells Fargo & Company from $95.00 to $140.00. They now have an "equal weight" rating on the stock.MarketBeat
- GeneDx to Participate in Upcoming Investor ConferencesBusiness Wire
WGS
Earnings
- 10/28/25 - Beat
WGS
Sec Filings
- 12/3/25 - Form 4
- 11/26/25 - Form 4
- 11/24/25 - Form 144
- WGS's page on the SEC website